India’s Sun Pharma Warns Taro Board Against Selling Irish Plant
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - India's Sun Pharmaceutical has warned the board of Israel's Taro Pharmaceutical to halt moves to sell a drug manufacturing unit in Ireland as the two firms dispute whether a year-old merger agreement remains in effect
You may also be interested in...
India’s Sun Pharma Begins Open Offer For Taro at $7.75
NEW DELHI - India's Sun Pharma said its Alkaloida Chemical unit started a tender offer for all shares of Israel's Taro Pharmaceutical as part of a disputed $460 million merger agreement reached a year ago, but unilaterally cancelled by Taro in late May
India’s Sun Pharma Begins Open Offer For Taro at $7.75
NEW DELHI - India's Sun Pharma said its Alkaloida Chemical unit started a tender offer for all shares of Israel's Taro Pharmaceutical as part of a disputed $460 million merger agreement reached a year ago, but unilaterally cancelled by Taro in late May
PharmAsia News Notable Notes: Citigroup Reiterates Buy On India’s Sun Pharma
NEW DELHI - Citigroup Global Markets reiterated its buy on Sun Pharma, India's largest drug company by market capitalization, saying a recent price dip related to a disputed merger attempt with Israel's Taro Pharma offers a "window of opportunity.